Viking Therapeutics, Inc. (VKTX)
NASDAQ: VKTX · Real-Time Price · USD
32.57
-1.14 (-3.38%)
At close: Jul 31, 2025, 4:00 PM
32.60
+0.03 (0.09%)
After-hours: Jul 31, 2025, 7:59 PM EDT
Viking Therapeutics Employees
Viking Therapeutics had 36 employees as of December 31, 2024. The number of employees increased by 9 or 33.33% compared to the previous year.
Employees
36
Change (1Y)
9
Growth (1Y)
33.33%
Revenue / Employee
n/a
Profits / Employee
-$4,765,194
Market Cap
3.66B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 36 | 9 | 33.33% |
Dec 31, 2023 | 27 | 6 | 28.57% |
Dec 31, 2022 | 21 | 3 | 16.67% |
Dec 31, 2021 | 18 | -2 | -10.00% |
Dec 31, 2020 | 20 | 1 | 5.26% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
VKTX News
- 6 days ago - Viking Therapeutics Q2: Confidently Continuing The Recovery - Seeking Alpha
- 8 days ago - Viking Therapeutics, Inc. (VKTX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 15 days ago - Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025 - PRNewsWire
- 21 days ago - Viking Therapeutics: What's Next After GLP-1 Hype Dies Down And Competition Intensifies - Seeking Alpha
- 4 weeks ago - Viking: I'm Bullish On Oral/Injectable GLP-1 Obesity Data Catalysts - Seeking Alpha
- 5 weeks ago - What's Going On With Viking Therapeutics Stock On Wednesday? - Benzinga
- 5 weeks ago - Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735 - PRNewsWire